Arbeitsgemeinschaft Knochentumoren e. V. (agkt)

• Literatur

• 1 Coulie PG. et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135-146.
• 2 Mellman I. et al. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489.
• 3 Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348: 69-74.
• 4 Lawrence MS. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.
• 5 Pugh TJ. et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45: 279-284.
• 6 Tirode F. et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014; 04: 1342-1353.
• 7 Baldauf MC. et al. Systematic identification of cancer-specific MHC-binding peptides with RAVEN. bioRxiv 193276. 2017 doi:10.1101/193276
• 8 Oberthuer A. et al. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004; 10: 4307-4313.
• 9 Foell JL. et al. Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer 2008; 51: 228-234.